{"id":"NCT05386680","sponsor":"Novartis Pharmaceuticals","briefTitle":"Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam","officialTitle":"Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-12","primaryCompletion":"2024-11-29","completion":"2024-11-29","firstPosted":"2022-05-23","resultsPosted":"2025-06-03","lastUpdate":"2025-06-03"},"enrollment":27,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Muscular Atrophy"],"interventions":[{"type":"GENETIC","name":"OAV101","otherNames":["AVXS-101","Zolgensma"]}],"arms":[{"label":"OAV-101","type":"EXPERIMENTAL"}],"summary":"This was a Phase IIIb open-label, single arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101B in participants with SMA aged 2 to \\<18 years after the discontinuation of treatment with nusinersen or risdiplam. The study aimed to enroll approximately 28 participants across each of 2 age brackets (2 to \\<6 years, and 6 to \\<18 years).","primaryOutcome":{"measure":"Overview of Treatment-emergent Adverse Events by Age Subgroup","timeFrame":"Adverse events were reported from single dose of study treatment plus 52 weeks, up to a maximum time period of 52 weeks.","effectByArm":[{"arm":"OAV101 1.2x1014 vg - All Participants","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":13,"countries":["United States","Australia","Belgium","Canada","France","Italy","Japan","Netherlands","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":27},"commonTop":["Nasopharyngitis","Vomiting","Pyrexia","Headache","Abdominal pain upper"]}}